CAS: 99-42-3; Methyl 4-Hydroxy-3-Nitrobenzoate

上下游产品

CAS号67-56-1 甲醇 | CAS号616-82-0 3-硝基-4-羟基-苯甲酸 | CAS号144-55-8 碳酸氢钠 | CAS号99-76-3 尼泊金甲酯 | CAS号7664-93-9 硫酸 | CAS号420-37-1 三甲基氧鎓四氟硼酸 | CAS号107-06-2 1,2-二氯乙烷 | CAS号40258-72-8 3-溴-4-羟基-5-硝基苯甲酸甲酯 | CAS号260249-10-3 3-氨基-5-溴-4-羟基苯甲酸甲酯 | CAS号758684-29-6 3,4-二氢-2H-苯并[1,... | CAS号536-25-4 3-氨基-4-羟基苯甲酸甲酯 | CAS号136663-21-3 2-甲基苯并[d]噁唑-5-羧酸甲酯 | CAS号1571-72-8 3-氨基-4-羟基苯甲酸 | CAS号202195-67-3 3-氧代-3,4-二氢-2H-... | CAS号120629-58-5 Benzamide, 3-am... | CAS号70382-03-5 4-hydroxy-3-nit... | CAS号663625-64-7 methyl 3-nitro-...

对羟基苯甲酸甲酯置于silica Supported Al(No3)3*9H2O体系中,用 丙酮 作为反应溶剂,化学反应 0.75H,以98%的收率获得产物3-硝基-4-羟基苯甲酸甲酯
参考文献:硝酸铝在二氧化硅上硝化体系对苯酚和苯醚的区域选择性硝化
标题:硝酸铝在二氧化硅上硝化体系对苯酚和苯醚的区域选择性硝化
摘要:发现二氧化硅负载的硝酸铝(al(no3)3.9H2O)是用于苯酚和苯基醚硝化的极好试剂.该方法在室温下对大多数实施例有效地进行,以高的区域选择性以中等至非常好的产率产生硝基衍生物.本方法论证明了反应速率的显着提高以及高的o-选择性,优异的产率,易于处理和后处理简单.
DOI:10.2174/1570178612666150108000402

专利信息

专利号:US-8304409-B2
优先权日:2002-07-03
标 题:Nitrosated nonsteroidal antiinflammatory compounds, compositions and methods of use
发明人：EARL RICHARD A; EZAWA MAIKO; FANG XINQIN; GARVEY DAVID S; GASTON RICKY D; KHANAPURE SUBHASH P; LETTS L GORDON; LIN CHIA-EN; RANATUNGE RAMANI R; RICHARDSON STEWART K; SCHROEDER JOSEPH D; STEVENSON CHERI A; WEY SHIOW-JYI
权利人:EARL RICHARD A; EZAWA MAIKO; FANG XINQIN; GARVEY DAVID S; GASTON RICKY D; KHANAPURE SUBHASH P; LETTS L GORDON; LIN CHIA-EN; RANATUNGE RAMANI R; RICHARDSON STEWART K; SCHROEDER JOSEPH D; STEVENSON CHERI A; WEY SHIOW-JYI; NICOX SA
摘要:The invention describes novel nitrosated nonsteroidal antiinflammatory drugs (NSAIDs) and pharmaceutically acceptable salts thereof, and novel compositions comprising at least one nitrosated NSAID, and, optionally, at least one compound that donates, transfers or releases nitric oxide, stimulates endogenous synthesis of nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor or is a substrate for nitric oxide synthase, and/or at least one therapeutic agent. The invention also provides novel compositions comprising at least one nitrosated NSAID, and at least one compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase and/or at least one therapeutic agent. The invention also provides novel kits comprising at least one nitrosated NSAID, and, optionally, at least one nitric oxide donor and/or at least one therapeutic agent. The invention also provides methods for treating inflammation, pain and fever; for treating gastrointestinal disorders; for facilitating wound healing; for treating and/or preventing gastrointestinal, renal and/or respiratory toxicities resulting from the use of nonsteroidal antiinflammatory compounds; for treating inflammatory disease states and/or disorders; and for treating and/or preventing ophthalmic diseases and/or disorders.